JAKARTA - PT Bio Farma (Persero) said that as many as 4 million doses of the Covid-19 vaccine have been produced and are ready to be distributed in February 2021.
"As of Thursday, January 21, there have been 4 million doses that have been produced. The status of these products is in the process of quality control, which will be sent to the POM to get a lot release so that it can be distributed, and it is estimated that until February. In the coming 2021, 4 million doses of vaccine will be ready, "said Director of Bio Farma, Honesti Basyir in an official statement received in Jakarta, reported by Antara, Saturday, January 23.
He said Bio Farma had received 15 million bulk doses of the Covid-19 vaccine from Sinovac, on January 12. Then Bio Farma continues the production process from raw materials to become the final product.
In total, Bio Farma will receive as many as 140 million doses of the Sinovac vaccine raw material which will be received in stages.
He said the results from the raw material production process would complement the supply of the COVID-19 vaccine in three doses of the finish product that was received previously in December 2020.
"The collaboration between Bio Farma and Sinovac uses two mechanisms, namely imports in the form of finished goods or single dose finished products intended for front liners in Indonesia, and imports in bulk form or vaccine concentrate. From this bulk, it will be further processed at Bio Farma in Indonesia. the existing fill and finish facilities at Bio Farma, "said Honesti.
For vaccine distribution, he continued, the Bio Farma group together with PT Kimia Farma Tbk and PT Indofarma Tbk already have 48 branches or warehouses that can be optimized.
"In terms of technology, Bio Farma has prepared end-to-end digital solutions starting from the production plant, distribution process and arriving at the final destination (health facilities). And this distribution process can be monitored real time at the Command Center of BUMN Holding. Pharmacy, "he said.
He conveyed that Indonesia needed 181.5 million Covid-19 vaccines, or the equivalent of 426 million doses.
To anticipate the scarcity of supply of the Covid-19 vaccine from producers, it is said that the Indonesian government through the Ministry of Health has issued Permenkes Number HK.01.07 / MENKES / 12758/2020 concerning the Determination of Vaccines for Implementation of Coronavirus Disease 2019 (Covid-19) Vaccination.
From this Permenkes, the supply of vaccines will be obtained from the production of PT Bio Farma (Persero), AstraZeneca, China National Pharmaceutical Group Corporation (Sinopharm), Moderna, Pfizer Inc. and BioNTech and Sinovac Life Sciences Co., Ltd and Novovax. Of course, the entire Covid-19 vaccine must report the results of Clinical Trials 1 to 3, and obtain EUA from the POM.
The English, Chinese, Japanese, Arabic, French, and Spanish versions are automatically generated by the system. So there may still be inaccuracies in translating, please always see Indonesian as our main language. (system supported by DigitalSiber.id)